Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

2026-06-04
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wolfe Research Assumes Revvity at Peer Perform

2026-06-02
Wolfe Research analyst Mike Polark assumes Revvity (NYSE:RVTY) with a Peer Perform rating.

Research Tools & Consumables Stocks Q1 In Review: Revvity (NYSE:RVTY) Vs Peers

2026-06-01
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at research tools & consumables stocks, starting with Revvity (NYSE:RVTY).

Is Danaher Stock Underperforming the S&P 500?

2026-05-29
Danaher has underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

Which S&P500 stocks have an unusual volume on Thursday?

2026-05-28
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Thursday. Stay informed about the market activity below.

Revvity Stock: Analyst Estimates & Ratings

2026-05-22
Revvity has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings

2026-05-20
Revvity, Inc.'s ( NYSE:RVTY ) stock was strong despite it releasing a soft earnings report last week. We think that...

The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call

2026-05-15
Revvity’s first quarter results were well received by the market, as the company delivered stronger-than-expected organic growth and margins. Management attributed the positive performance to solid execution in both the Life Sciences and Diagnostics segments, with particular momentum in reagents, instruments, and reproductive health. CEO Prahlad Singh highlighted that “the better-than-anticipated revenue and margin performance” reflected resilience across key customer groups, including pharma, b

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

2026-05-14
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

2026-05-13
Revvity, Inc. (RVTY) Bank of America Global Healthcare Conference 2026 May 13, 2026 12:20 PM EDTCompany ParticipantsStephen Willoughby - Senior VP of...